Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

NCT05768945 · Completed

Last updated 2026-05-28

This clinical trial is comparing the effects of semaglutide to DPP4 inhibitors on the time it takes for people with diabetes to develop dementia.

Status Completed The study has finished.

Type Observational

Participants 742,670 people

Who can join Ages 65+ · all sexes Healthy volunteers accepted.

Timeline Started 2022-11 · est. completion 2023-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05768945 ↗

Description as written by the study sponsor.

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Treatments tested

Semaglutide Drug

Semaglutide claim is used as the exposure group.
DPP-4 inhibitor Drug

DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) claim is used as the reference group.

Main thing measured	Time to Dementia Onset
Sponsor	Brigham and Women's Hospital
Conditions studied	Diabetes
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05768945 ↗